AIDS 20 Years Later...

On June 5, 1981, a one-and-a-half page paper in Morbidity and Mortality Weekly Report (MMWR) noted cases of Pneumocystis carinii pneumonia in five gay men in Los Angeles. The men also suffered from cytomegalovirus (CMV) infections and candidal infections of the mucosa,1 and they used recreational inhalant drugs. The editorial note pointed out: "Pneumocystis pneumonia in the United States is almost exclusively limited to severely immunosuppressed patients." "I was sitting in my office in Buildi

Written byMyrna Watanabe
| 11 min read

Register for free to listen to this article
Listen with Speechify
0:00
11:00
Share

"I was sitting in my office in Building 10,2 going through my usual work and lab data, and I got that first issue ... and I thought this was really odd," recalls Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID). He recalls getting a "funny feeling" about it. "I don't like these unresolved things. Was this a bad batch of drugs? I never even imagined at that point that this was a new virus at all."

A month later, another MMWR report linked Pneumocystis infection in gay men with a rare cancer: Kaposi's sarcoma (KS).3 This cancer was diagnosed in 20 men in New York City and six in California; six of the 26 had pneumonia. Ten other cases of Pneumocystis pneumonia were diagnosed in California. With that second report, Fauci remembers thinking, "'Whoa; we have a problem; this sounds very much like an underlying ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies